SEALSQ Enhances INeS PKI Platform with Code Signing Capability to Secure Firmware Integrity in Alignment with RED and CRA Regulations

Geneva, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced a significant enhancement to its trusted INeS PKI platform, which now includes secure code signing services designed to protect the integrity of firmware distributed across connected devices. This new capability positions INeS as a future-proof trust infrastructure for manufacturers needing to secure over-the-air (OTA) firmware updates in compliance with emerging global cybersecurity regulations.

INeS now supports firmware signing with both legacy ECC (Elliptic Curve Cryptography, RSA algorithms, enabling customers to meet today’s performance and regulatory needs while preparing for the quantum era.

“With global regulations such as the EU Cyber Resilience Act, NIS2, and U.S. Executive Order 14028 raising the bar on software supply chain security, firmware integrity has become mission-critical,” said Gweltas Radenac, IoT Security Business Line Director of SEALSQ. “By integrating code signing into our INeS platform, SEALSQ delivers a scalable, standards-based, and post-quantum-ready trust infrastructure for OEMs across IoT, Medical Device, and critical infrastructure such as Smart Grid.”

End-to-End Firmware Protection via INeS

The upgraded INeS platform now offers:

  • Secure code signing authority integrated into the INeS PKI
  • Flexible signature algorithms: ECC (e.g., ECDSA, EdDSA)
  • Key and certificate lifecycle management for firmware signing keys
  • Compliance-ready trust policies aligned with ETSI EN 319 421, ISO/IEC 27001, NIST SP 800-57
  • Support for offline signing (air-gapped facilities) and secure signing via HSM
  • Secure timestamping and signature metadata generation for auditability

Responding to a New Regulatory Landscape

This strategic enhancement to INeS aligns with new and pending regulations that require software publishers to guarantee the authenticity and integrity of software components:

  • EU Cyber Resilience Act (CRA): mandates signed firmware and vulnerability disclosure obligations
  • UN R155 / ISO/SAE 21434 (automotive): demands cryptographic integrity of OTA updates
  • U.S. Executive Order 14028: emphasizes software supply chain integrity and SBOM traceability
  • ETSI EN 303 645 & NIST IR 8259: recommend secure update mechanisms and signed firmware for IoT

Post-Quantum Readiness Built In

With quantum computing threatening the long-term security of current cryptographic schemes, INeS integrates Post-Quantum certificate support, enabling customers to:

  • Sign firmware using both ECC algorithms
  • Deploy crypto-agile mechanisms in existing hardware

A Trusted Platform for IoT & Beyond

INeS is used by global manufacturers to inject and manage digital identities for over 30 million smart meters and industrial IoT devices worldwide. With this new code signing extension, OEMs can now leverage the same infrastructure to ensure firmware authenticity, integrity, and compliance, from chip to cloud.

About SEALSQ:

SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable.

SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries.

For more information on our Post-Quantum Semiconductors and security solutions, please visit www.sealsq.com.

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements concerning SEALSQ Corp and its businesses. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, events or developments that we expect or anticipates will occur in the future, as well as any other statements which are not historical facts. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include SEALSQ’s ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; and the risks discussed in SEALSQ’s filings with the SEC. Risks and uncertainties are further described in reports filed by SEALSQ with the SEC.

SEALSQ Corp is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SEALSQ Corp.
Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
[email protected]
SEALSQ Investor Relations (US)
The Equity Group Inc.
Lena Cati
Tel: +1 212 836-9611
[email protected]



FAST TRACK GROUP Issues Letter to Shareholders to Discuss Recent Business Developments and Future Growth Strategies

SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) — FAST TRACK GROUP (NASDAQ: FTRK) (“Fast Track” or the “Company”), an entertainment-focused event management and celebrity agency company, today issued a letter to its shareholders highlighting the future business outlook and strategy of the Company.

From FAST TRACK GROUP Chief Executive Officer Harris Lim

Dear Shareholders,

First, I want to extend my sincere appreciation for your patience, trust and continued support over the past few months. Since our IPO in May 2025, our journey as a public company has unfolded under unusual circumstances, as we faced a wave of misleading allegations that have impacted both our company and shareholders. In response, we issued this press release that combatted the false rumors and accusations – I want to personally guarantee everyone reading this letter and beyond, that the fundamentals of our business have not changed, and that we are very excited for the upcoming chapters for Fast Track.

Our Upcoming Opportunities

Over the past several months, we have concentrated our efforts on major brand activation initiatives – engaging with a diverse range of companies and brands across Southeast Asia and aligning them with high-profile celebrities whose audiences align closely with each brand’s target market. By creating these highly targeted and authentic endorsements, we are not only elevating brand visibility but also driving awareness and conversion potential in a way that is tailored to each market.

As an example, during the second half of 2024, we secured a brand activation deal valued at approximately $1.3 million with a new client and executed in collaboration with multinational talent and entertainment agencies. This three-part project – of which the first two phases were completed in May and July – centers on South Korean celebrities from these prominent agencies, carefully matched to the client’s target audience to maximize engagement and impact. The final phase is scheduled for October, at which point we plan to share additional details. Notably, this single deal already exceeds our total revenue for fiscal year ended February 28, 2025, underscoring the scale of this deal to accelerate growth.

Another recent brand activation deal was with an electric vehicle (EV) brand in the Southeast Asia market. Similar to the previous example, we were contracted to drive market penetration and support the brand’s marketing and positioning efforts in advance of a new product launch. The EV brand’s priority was to capture attention and generate strong publicity around this particular product launch. Leveraging our network and expertise, we identified and secured celebrity partnerships whose audiences align closely with the EV brand’s target market, helping amplify awareness, spark consumer interest, and create a buzz in the highly competitive Southeast Asian EV landscape. By strategically facilitating these partnerships, we provided the brand with a tailored and impactful marketing solution that differentiated them in a crowded field.

These examples represent a glimpse of the opportunities our team has been actively pursuing. We continue to explore and engage with new clients and partners across the Southeast Asia market, identifying ways to deliver our services and create meaningful experiences. Our efforts are focused on deepening our market presence, building strong relationships, and driving sustainable growth throughout the region.

Current Market Shift in the Live Entertainment Sector

While these opportunities are encouraging, we remain forward-looking, continuously exploring innovative ways to adapt our business model to evolving market trends and conditions. Traditionally, a significant portion of our live entertainment work was focused on concert organization. However, current market dynamics have made this approach increasingly challenging and risky, as concert organizers currently face low profitability and many smaller-scale events fail to generate meaningful returns. Additionally, the traditional concert model is difficult to scale, especially at our current size, due to the significant cash flow and manpower required.

That said, our growth strategy and how we approach future opportunities emphasizes both profitability and scalability. Strategically, we have shifted our focus from concert organization to concert tour management. This evolution aligns with current market realities while supporting our broader objective of innovating and adapting our business model.

This distinction is critical: as a concert organizer, especially at our current size, the risk lies with the venue, ticketing, cancellation, and other operational costs for a single event. By contrast, as a tour manager, we can leverage the same budget of a single concert to secure specific celebrity rights, which can then be offered to multiple concert organizers. This model mitigates the financial risks associated as an organizer while enhancing profitability and is more scalable. Instead of focusing on a single concert, we can supply celebrity talent to multiple organizers simultaneously, creating diversified revenue streams and maximizing the impact of our resources. This strategic pivot positions us to grow efficiently while maintaining flexibility and resilience in this market.

As part of this shift, we’ve already begun putting our new business model into action. We are currently in discussions to finalize two concert tours for a few celebrities in the Asia region. That said, this does not mean we are exiting the concert organizer business entirely. We will remain opportunistic – leveraging our extensive network of celebrities, we are prepared to organize concerts directly when opportunities align with a clear ROI. Our goal is to remain agile in response to evolving market trends and shifts within the live entertainment sector. With experience as both a concert organizer and a tour manager, we can adapt to changing conditions, seize the right opportunities, and maintain flexibility while driving sustainable growth. This dual capability positions us to respond strategically, ensuring long-term relevance and profitability in a dynamic market.

Future Growth Strategy

To further accelerate our growth in celebrity-driven initiatives, building strategic partnerships with key firms in the entertainment and media industry remains a central focus. Collaborating with agencies to deliver enhanced services to our clients and cultivating strong industry relationships are both essential to our success in the broader entertainment ecosystem.

This approach is evident in the example I shared earlier, where we collaborate with several agencies representing high-profile celebrities to facilitate the three-part brand activation project.

Additionally, while still in the early stages, we are exploring opportunities to consolidate intellectual property, artist ownership, and music licensing rights. This initiative would allow us to secure exclusive celebrity rights, enabling us to more effectively facilitate concerts, brand activations, and marketing projects, while expanding the range and depth of services we can offer our clients.

In an industry where relationships are key to unlocking new business opportunities, we recognize that results may not always be immediate; however, by continuing to invest time and effort into this initiative, we are positioning ourselves for sustainable long-term growth.

Closing Remarks

In closing, we see strong opportunities ahead as we work with our clients to finalize the deals currently in progress. The brand activation projects and other upcoming opportunities highlighted earlier represent just a small portion of our broader pipeline and will play a key role as growth drivers as we continue to scale the business. We remain confident in the progress made across our pipeline since our IPO and look forward to sharing further details, along with additional opportunities, as they are finalized.

We sincerely thank all our shareholders and supporters for their continued trust and support as we navigate this unique journey in the market. Our focus remains firmly on building strategic partnerships, delivering consistent value to our clients, and scaling our business to generate sustainable, long-term results.

Sincerely,
Harris Lim
Chief Executive Officer and Director

About FAST TRACK GROUP

FAST TRACK GROUP is a leading entertainment-focused event management and celebrity agency company. Since inception in Singapore in 2012, the Company has expanded across Asia Pacific, earning a reputation for being the preferred partner for event and endorsement organizers in the region. FAST TRACK GROUP goes beyond traditional event management, offering value-added services such as media planning, PR management, technical production planning, celebrity sourcing, celebrity engagement consultancy and event manpower support, all tailored to the highest standards.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.

Investor Relations

Gateway Group, Inc.
949-574-3860
[email protected]



Streamex (BSGM) to Participate in the 5th Annual Needham Virtual Crypto 1×1 Conference on September 4th

LOS ANGELES, CA & VANCOUVER, BC , Aug. 28, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), a gold tokenization infrastructure company building the foundation for on-chain gold markets, today announced that it will participate in the 5th annual Needham Virtual Crypto 1×1 Conference on September 4th, 2025. BioSig and Streamex CEO, Henry McPhie and CIO, Mitch Williams will host one on one meetings with institutional investors at the conference.

About Streamex

Streamex is an RWA and gold tokenization company building Institutional grade infrastructure to bring the gold market on chain, enabled by a gold denominated treasury and tokenization technology powering the gold market of tomorrow.  Streamex is a wholly owned subsidiary of BioSig Technologies, Inc.

About BioSig Technolgies

BioSig Technologies, Inc. is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP™ Platform that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias.



Contacts

BioSig/Streamex Press & Investor Relations:

Adele Carey
Alliance Advisors Investor Relations
[email protected]

Henry McPhie
CEO of BioSig, Co-Founder of Streamex
[email protected]
[email protected]
https://www.streamex.com/
https://x.com/streamex

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8-10, 2025, in New York.


Presentation Details

Date/ time: Tuesday, September 9 at 3:30 PM ET
Location: Lotte New York Palace Hotel
Webcast link: click here

The webcast will be available for 90 days at the link above or on the Aprea Investors page, under “News & Events.”

About Aprea
Aprea’s mission is to develop novel cancer therapies that target cancer cells directly, while sparing healthy ones. By exploiting unique vulnerabilities in cancer cell mutations, this approach is designed to eradicate tumors while minimizing harm to normal tissues, thereby reducing the risk of toxicity often associated with conventional chemotherapy and other treatments. Aprea’s lead programs include APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a macrocyclic small molecule ATR inhibitor, both currently in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Investor Contact:

Mike Moyer
LifeSci Advisors
[email protected]



Sycamore Partners Completes Acquisition of Walgreens Boots Alliance

Sycamore Partners Completes Acquisition of Walgreens Boots Alliance

NEW YORK–(BUSINESS WIRE)–
Sycamore Partners (“Sycamore”) announced today that it has completed its acquisition of Walgreens Boots Alliance, Inc. (the “Company” or “WBA”).

Sycamore is acquiring the business in partnership with Stefano Pessina and his family, who have reinvested 100% of their interests in WBA, demonstrating their ongoing support and confidence in the Company’s future.

Stefan Kaluzny, Managing Director of Sycamore, said, “Walgreens Boots Alliance, Inc., its companies and its dedicated team members play an essential role in the communities they serve around the world. We look forward to partnering with the management teams at each company, including Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD. As standalone companies under private ownership, they will build on their proud legacies to enhance the customer experience and deepen the trusted relationships they have earned with millions of customers around the world.”

Stefano Pessina said, “This milestone begins a new chapter for Walgreens, The Boots Group and the other portfolio businesses. Our family has proudly supported these companies for decades, and we are pleased to continue that commitment alongside Sycamore. Together, we are united in our belief in the future of these organizations and the essential role they play in millions of lives each day.”

Following the closing of the transaction, Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD will operate as separate standalone companies.

With the completion of the acquisition, WBA’s common stock has ceased trading and will no longer be listed on the Nasdaq. In addition to their cash consideration of $11.45 per WBA share, WBA shareholders will receive one non-transferable right to receive up to an additional $3.00 in cash per WBA share from the net proceeds of the future monetization of WBA’s debt and equity interests in VillageMD, which includes the Village Medical, Summit Health and CityMD businesses.

Advisors

UBS Investment Bank is acting as lead financial advisor, Goldman Sachs and J.P. Morgan are acting as co-lead financial advisors, Citi and Wells Fargo are acting as financial advisors, Davis, Polk & Wardwell LLP is acting as legal counsel and Bass Berry & Sims PLC is acting as healthcare regulatory counsel to Sycamore.

Centerview Partners is acting as financial advisor, Kirkland & Ellis LLP is acting as legal advisor and Ropes & Gray LLP is acting as healthcare regulatory counsel to WBA. Morgan Stanley & Co. LLC was also a financial advisor, and provided a fairness opinion to the WBA Board of Directors.

Debevoise & Plimpton LLP is acting as legal advisor to Stefano Pessina.

WBA Contact

Jonathon Hosea

[email protected]

Sycamore Contacts

Michael Freitag, Zach Genirs, Abigail South

Joele Frank, Wilkinson Brimmer Katcher

212-355-4449

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Health Cosmetics Retail Pharmaceutical Specialty

MEDIA:

Logo
Logo

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Data establish maximum tolerated dose, supporting progression of lead neuroplastogen compound EB-003 toward IND-enabling studies and First-in-Human clinical trials

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics for the treatment of depression, post-traumatic stress disorder (PTSD), and other neuropsychiatric disorders, today announced the successful completion of 7-day Dose Range Finding (DRF) toxicology studies in two preclinical species for its lead drug candidate, EB-003. The results define the Maximum Tolerated Dose (MTD) and represent a key pipeline advancement landmark supporting the Company’s IND-enabling activities and preparation for First-in-Human clinical trials.

The DRF studies were designed to evaluate toxicity and toxicokinetics following daily oral dosing of EB-003, Enveric’s first-in-class neuroplastogen candidate that selectively engages serotonin 5-HT2A and 5-HT1B receptors. The findings confirmed oral bioavailability in both species, with dose-dependent increases in plasma EB-003 concentrations observed across the tested range. At higher dose levels, central nervous system (CNS)-related effects were noted in both species, indicative of brain penetration and potential on-target activity. These results provide important safety and tolerability data to guide dosing strategies in future animal studies and First-in-Human studies.

“Completion of the DRF toxicology studies and establishment of the MTD in two preclinical species is a significant and necessary milestone in the development of EB-003,” said Dr. Joseph Tucker, Chief Executive Officer of Enveric. “These findings provide a well-defined reference point for planning human dosing and position us to advance EB-003 into definitive toxicology, safety pharmacology, and genotoxicity studies required for the IND submission to the FDA. This achievement moves us closer to clinical trial readiness for EB-003.”

Determining the MTD offers insight into the relationship between the anticipated therapeutic dose and toxic limits, a critical element in the regulatory pathway toward human testing. In addition, the reproducibility of CNS-related effects, and confirmation of oral bioavailability and brain penetration support the compound’s intended use and inform the design of upcoming studies.

EB-003 is a first-in-class, neuroplastogen designed to selectively engage serotonin 5-HT2A and 5-HT1B receptors, targets implicated in neuroplasticity and mood regulation, without inducing hallucinations. Preclinical findings to date support the potential of EB-003 to promote adaptive neural circuit remodeling in animals without inducing motor responses predictive of hallucinogenic effects in humans. These pharmacological characteristics potentially enable outpatient administration for chronic neuropsychiatric indications. EB-003 is advancing through preclinical development toward evaluation in human clinical trials.

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT2A and 5-HT1B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.

For more information, please visit www.enveric.com.

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “explores,” “schedules,” “seeks,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations

Tiberend Strategic Advisors, Inc.

David Irish

(231) 632-0002

[email protected]

Media Relations

Tiberend Strategic Advisors, Inc.

Casey McDonald

(646) 577-8520

[email protected]

KEYWORDS: United States North America Canada Massachusetts

INDUSTRY KEYWORDS: Mental Health Health FDA General Health Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

CrowdStrike to Webcast Investor Briefing

CrowdStrike to Webcast Investor Briefing

AUSTIN, Texas–(BUSINESS WIRE)–
CrowdStrike Holdings, Inc. (Nasdaq: CRWD), today announced that it will host a briefing for investors on September 17, 2025 during its Fal.Con 2025 customer conference.

Event:

CrowdStrike Investor Briefing

Location:

Las Vegas

Date:

Wednesday, September 17, 2025

Presentation time:

11:00 a.m. PDT

Space for the event is limited and pre-registration is required. Analysts and investors interested in attending are encouraged to contact Investor Relations at [email protected]. A live webcast and replay of the briefing will be accessible from the investor relations section of CrowdStrike’s website at ir.crowdstrike.com.

About CrowdStrike Holdings

CrowdStrike (Nasdaq: CRWD), a global cybersecurity leader, has redefined modern security with the world’s most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data.

Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities.

Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value.

CrowdStrike: We stop breaches.

For more information, please visit: ir.crowdstrike.com

© 2025 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services.

Investor Relations Contact

CrowdStrike Holdings, Inc.

Maria Riley

[email protected]

669-721-0742

KEYWORDS: Nevada California Texas United States North America

INDUSTRY KEYWORDS: Data Management Communications Security Technology Software Artificial Intelligence Public Relations/Investor Relations

MEDIA:

Logo
Logo

Pagaya to Participate in Upcoming September Investor Conferences and Events

Pagaya to Participate in Upcoming September Investor Conferences and Events

NEW YORK–(BUSINESS WIRE)–
Pagaya Technologies Ltd. (“Pagaya” or the “Company”), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced that the Company’s management team will participate in the following investor conferences:

Jefferies FinTech Conference

Date: September 3, 2025

Location: New York, NY

Benchmark TMT Conference

Date: September 4, 2025

Location: New York, NY

EY JournEY

Date: September 9, 2025

Location: Tel Aviv, IL

Jefferies Tech Trek

Date: September 11, 2025

Location: Tel Aviv, IL

About Pagaya

Pagaya (NASDAQ: PGY) is a global technology company making life-changing financial products and services available to more people nationwide, as it reshapes the financial services ecosystem. By using machine learning, a vast data network and an AI-driven approach, Pagaya provides comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its proprietary API and capital solutions integrate into its network of partners to deliver seamless user experiences and greater access to the mainstream economy. Pagaya has offices in New York and Tel Aviv. For more information, visit pagaya.com.

Investors & Analysts

Josh Fagen

Head of Investor Relations & COO of Finance

[email protected]

KEYWORDS: United States North America Israel Middle East New York

INDUSTRY KEYWORDS: Technology Other Professional Services Finance Apps/Applications Other Construction & Property Banking Residential Building & Real Estate Professional Services Construction & Property Artificial Intelligence Other Technology Software Fintech Data Management

MEDIA:

Logo
Logo

Alarum Technologies Announces Second Quarter 2025 Results


Deepening collaborations with major global customers while accelerating investments in



technology and talent to cement Alarum’s key positioning in the AI value chain


Q2 2025 revenues of $8.8 million, net profit of $0.3 million, and Adjusted EBITDA of $1.0 million

TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) — Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of web data collection solutions, today announced financial results for the six- and three-month periods ended June 30, 2025.

Management Commentary

“Our focus and progress this quarter, as well as our outlook, are mainly driven by very strong demand for data from major global players in the artificial intelligence (AI) segment for training large language and other foundational models,” commented Shahar Daniel, Chief Executive Officer of Alarum. “Alarum’s market-leading data collection solutions are increasingly gaining traction with global leaders. Several leading AI and e-commerce companies have significantly expanded their usage of our services, relying on our advanced data collection global platform and products to fuel their large-scale data needs and initiatives. This highlights the strategic partnerships we are building with leading global customers, expanding our market presence and strengthening Alarum’s role as a trusted long-term strategic partner in the AI global ecosystem.”

“We are very proud of the growth achieved in the quarter and encouraged by the higher revenue levels we believe we will see in the upcoming quarter. The AI segment is in its early growth stages, which is likely to be highly dynamic in nature as it progresses towards maturity. The entire market and all its players along the value chain, including our customers, are in the middle of a major transformation and exploring various business models with an eye towards profitability. As AI business models evolve over the quarters ahead, we may experience volatility in demand and usage of our platform, potentially influencing short-term quarterly financial performance, even while the long-term growth trend remains intact and significant. We strongly believe that the new capabilities and applications enabled by AI are here to stay for the long-term, and we are investing to ensure Alarum cements itself as a central player in this new era.”

Mr. Daniel continued: “Our technology is increasingly recognized by customers as a critical enabler of the AI boom, which is powering today’s surge in the demand for large-scale data. We believe that Alarum is exactly in the right place at the perfect time at the heart of the AI revolution, with tremendous opportunities ahead. Through continued investments in expanding our infrastructure, R&D, talent, marketing, sales and customer acquisition, we aim to position Alarum to capture the opportunities ahead and drive a long-term trajectory of revenue growth and high profitability.”

Business Highlights

–  Expanded traction with major AI and e-commerce players – new strategic collaborations include a top Asian online marketplace developing its own large language model, a global electronics brand, and a European AI firm leveraging Alarum’s platform and products for large-scale data labeling and model fine-tuning.

–  Strategic investments for a sustainable growth – the Company is investing in its infrastructure, up-scaling operations, and strengthening its global proxy network to support the booming market demand, while maintaining high operational efficiency.

–  Visibility and a highly dynamic pipeline – the Company expects a substantial increase in revenues in the third quarter of 2025. At the same time, the AI market is undergoing a profound transformation, with many AI companies still defining their business model in this new world. This dynamism may result in both positive and negative fluctuations in Alarum’s quarterly revenue levels along the way.

–  Strengthened product portfolio – the growing demand for Alarum’s primary subsidiary, NetNut Ltd.’s (“NetNut”) data collection suite, including NetNut’s Data Collector (Serp API), data sets, Website Unblocker and advanced proxy network, is increasingly contributing to the Company’s total revenues.

–  Significant shift in market verticals – the Company is experiencing a notable shift in customer segments, with strong growth in the AI vertical, offset by a decline in others. As a result, the Net Retention Rate (“NRR”) was 0.98, while overall revenues grew significantly versus the prior quarter.

Summary of Financial Results
1

(in millions of U.S. dollars, rounded, except per share amounts and margins)

    For the Six Months Ended

June 30,
    For the Three Months Ended

June 30,
    For the Year Ended December 31,  
    2025     2024     2025     2024     2024  
    (Unaudited)     (Unaudited)     (Unaudited)     (Unaudited)     (Audited)  
Revenue     15.9       17.3       8.8       8.9       31.8  
Gross profit     10.2       13.4       5.4       6.8       23.9  
Gross margin (in percentage)     64.3 %     77.7 %     61.7 %     76.9 %     75.1 %
Non-IFRS gross margin (in percentage)     66.0 %     79.9 %     63.3 %     78.5 %     77.0 %

2
Total operating expenses     9.9       8.1       5.4       4.2       17.2  
Financial income (expense), net     0.7       (3.3 )     0.4       (2.5 )     0.3  
Tax expense     0.3       0.8       0.1       0.5       1.2  
Net profit (loss) for the period     0.7       1.1       0.3       (0.4 )     5.8  
Adjusted EBITDA     2.3       6.6       1.0       3.4       9.42  
Basic earnings (loss) per American Depository Share (“ADS”) (in U.S. dollars)   $ 0.10     $ 0.16     $ 0.04     $ (0.05 )   $ 0.87  
Non-IFRS basic earnings per ADS (in U.S. dollars)   $ 0.32     $ 0.86     $ 0.17     $ 0.41     $ 1.262  
Cash, cash equivalents and debt investments (including accrued interest)3     25.0       21.6       25.0       21.6       25.0  
Shareholders’ equity3     29.1       20.4       29.1       20.4       26.4  

1 The table above contains certain non-IFRS financial measures. See “Use of Non-IFRS Financial Results” for additional information regarding these measures and reconciliations to the most comparable IFRS measures.
2 Unaudited
3 As of the last day of the period.

Second Quarter and First Half 2025 Financial Analysis

–  Revenue in Q2 2025 totalled $8.8 million (Q2 2024: $8.9 million) and $15.9 million for the first half of 2025 (H1 2024: $17.3 million). The revenues were impacted by market fluctuations. The decline in the half year results, compared to the equivalent period in 2024, was driven by a reduced consumption from several large customers due to changes in their businesses. In Q2 2025, revenues stabilized and showed growth momentum.

–  Cost of revenue in Q2 2025 was $3.4 million (Q2 2024: $2.1 million), and $5.7 million for the first six months of 2025 (H1 2024 $3.9 million). The increase was primarily driven by the Company’s work with large customers, primarily Artificial Intelligence (AI) companies, which require data gathering at significantly higher scales, in turn necessitating a larger volume of servers as well as stronger and higher-quality infrastructure.

–  Gross profit in Q2 2025 amounted to $5.4 million (Q2 2024: $6.8 million), and in H1 2025 $10.2 million (H1 2024: $13.4 million).

–  Operating expenses in Q2 2025 totalled $5.4 million (Q2 2024: $4.2 million), and $9.9 million in the first six months of 2025 (H1 2024: $8.1 million). The increase was mainly due to an increase in research and development expenses.

–  Financial income, net, in Q2 2025 was $0.4 million (Q2 2024: financial expense, net, of $2.5 million). The variance between periods was mainly due to the fair value increase of derivative financial instruments in the second quarter of 2024, resulting from the sharp share price rise during that period.

–  Net profit in Q2 2025 was $0.3 million (Q2 2024: a loss of $0.4 million), and $0.7 million in the first half of 2025 (H1 2024: $1.1 million).

–  As of June 30, 2025, shareholders’ equity increased to $29.1 million, up from $26.4 million as of December 31, 2024. The increase was due to the contribution of first half 2025 net profit.

–  Outstanding ordinary share count as of June 30, 2025, was approximately 70.2 million shares, or 7.0 million in US-listed ADSs.

Financial Outlook

“Looking ahead, we expect to see the strong momentum and traction for our products continue into the third quarter of 2025, and as such, we expect third quarter revenues of approximately $12.8 million ±7%, up 78% year-over-year and Adjusted EBITDA is expected to be approximately $1.1 million +/-$0.5 million,” said Mr. Shai Avnit, Chief Financial Officer of Alarum.

“This guidance includes the initial impact of a new large-scale AI data project with a major existing customer, which is expected to contribute approximately $3 million of revenue during the third quarter. We engaged in this project at rapid speed, prioritizing collaboration and execution with one of the world’s leading technology players. As we are still in the early ramp-up stages, it is not currently clear what the full scope and length of the project will be. Also at the initiation stages of this project, we are actively optimizing infrastructure and cost structures, and expect near-term profitability from this project to be limited. Given the size of the project, it is expected to have a noticeable impact on the Company’s overall profitability in the third quarter.

“We view this as a strategic collaboration and a significant step for Alarum to strengthen its positioning as a data collection leader for the AI market, with the potential to expand a key partnership with one of the world’s largest technology players.”, concluded Mr. Avnit.

The Company is unable to present a reconciliation of estimated Adjusted EBITDA to net profit as it is unable to predict with reasonable certainty, and without unreasonable effort, the impact and timing of certain expenses on net profit. The financial impact of these expenses is uncertain and is dependent on various factors, including timing, and could be material to consolidated statements of profit or loss and other comprehensive income (loss).

Second Quarter and First Half 2025 Financial Results Conference Call

Mr. Shachar Daniel, Chief Executive Officer of Alarum, and Mr. Shai Avnit, Chief Financial Officer of Alarum, will host a conference call today, August 28, 2025, at 8:30 a.m. ET, 5:30 a.m. Pacific time, 3:30 p.m. Israel, to discuss the second quarter of 2025 results and financial outlook, followed by a Q&A session.

To attend, log in here or dial one of the following numbers, a few minutes before the call starts: 1-877-407-0789 or 1-201-689-8562. If you are unable to connect using the toll-free number, please try the international dial-in number. An Israeli toll-free number is: 1 809 406 247. Participants will be required to state their name and company upon dialling in.

Replay: The conference call will be broadcast live and available for replay here, the day following the call.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Alarum is using forward-looking statements in this press release when it discusses strengthening collaborations with major global customers; the benefits and advantages of the Company’s solutions; the expected continued demand from AI and e-commerce players; the belief that the Company will see higher revenues in the upcoming quarter; the belief that the early-stage and dynamic AI market offers long-term growth despite short-term volatility in demand and usage of the Company’s platform, potentially influencing short-term quarterly financial performance; opportunities ahead; the view that its technology positions the Company as a key enabler of the AI revolution; plans to invest in infrastructure, R&D, talent, and customer acquisition to support sustainable growth and profitability; expectations for increased revenues in the third quarter of 2025; and its estimates regarding third quarter 2025 revenues and Adjusted EBITDA. Because such statements deal with future events and are based on Alarum’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Alarum could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Alarum’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and in any subsequent filings with the SEC. Except as otherwise required by law, Alarum undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Alarum is not responsible for the contents of third-party websites.


Condensed Consolidated Statements of Financial Position



(in thousands of U.S. dollars)

    June 30,     December 31,  
    2025     2024     2024  
    (Unaudited)     (Unaudited)     (Audited)  
Assets                  
Current assets:                  
Cash and cash equivalents     14,914       21,626       15,081  
Trade receivables, net     4,153       2,471       3,231  
Other receivables     735       961       503  
      19,802       25,058       18,815  
Non-current assets:                        
Long-term deposits     23       102       121  
Long-term restricted deposit     340       –       –  
Other non-current assets     82       94       85  
Property and equipment, net     138       119       130  
Right-of-use assets     82       638       498  
Deferred tax assets     689       298       422  
Debt investments at fair value through Other Comprehensive Income     9,385       –       9,256  
Debt investments at fair value through profit or loss     574       –       555  
Intangible assets, net     542       1,082       811  
Goodwill     4,118       4,118       4,118  
Total non-current assets     15,973       6,451       15,996  
Total assets     35,775       31,509       34,811  
                         
Liabilities and equity                        
Current liabilities:                        
Trade payables     518       570       251  
Other payables     2,696       3,058       4,484  
Current maturities of long-term loan     690       564       938  
Contract liabilities     2,526       2,285       1,987  
Derivative financial instruments     17       3,409       148  
Short-term lease liabilities     180       362       359  
Total current liabilities     6,627       10,248       8,167  
                         
Non-current liabilities:                        
Long-term lease liabilities     23       439       261  
Long-term loans, net of current maturities     –       398       32  
Total non-current liabilities     23       837       293  
Total liabilities     6,650       11,085       8,460  
                         
Equity:                        
Ordinary shares     –       –       –  
Share premium     113,092       108,963       111,892  
Other equity reserves     11,891       12,705       11,012  
Accumulated deficit     (95,858 )     (101,244 )     (96,553 )
Total equity     29,125       20,424       26,351  
Total liabilities and equity     35,775       31,509       34,811  


Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income (Loss)


(in thousands of U.S. dollars, except per share amounts)

    For the

Six Months Ended

June 30,
    For the

Three Months Ended

June 30,
    For the

Year Ended

December 31,
 
    2025     2024     2025     2024     2024  
    (Unaudited)     (Unaudited)     (Unaudited)     (Unaudited)     (Audited)  
Revenue     15,924       17,260       8,791       8,884       31,824  
Cost of revenue     5,683       3,854       3,365       2,051       7,915  
Gross profit     10,241       13,406       5,426       6,833       23,909  
                                         

Operating expenses:
                                       
Research and development     3,156       2,143       1,786       1,121       4,495  
Sales and marketing     3,906       3,372       2,079       1,647       7,033  
General and administrative     2,866       2,626       1,581       1,386       5,661  
Total operating expenses     9,928       8,141       5,446       4,154       17,189  
                                         
Operating profit (loss)     313       5,265       (20 )     2,679       6,720  
                                         
Financial income (expense), net     661       (3,345 )     449       (2,497 )     281  
                                         
Profit from operations before income tax     974       1,920       429       182       7,001  
Tax expense     279       831       142       533       1,221  
                                         
Net profit (loss) for the period     695       1,089       287       (351 )     5,780  
Other comprehensive income (loss) for the period                                        
Change in fair value of debt investments     121       –       49       –       (80 )
Total comprehensive income (loss) for the period     816       1,089       336       (351 )     5,700  
                                         
Basic profit (loss) per share   $ 0.01     $ 0.02       *     $ (0.01 )   $ 0.09  
Diluted profit (loss) per share   $ 0.01     $ 0.02       *     $ (0.01 )   $ 0.08  
Basic profit (loss) per ADS   $ 0.10     $ 0.16     $ 0.04     $ (0.05 )   $ 0.87  

*  Less than $0.01

Use of Non-IFRS Financial Results

In addition to disclosing financial results calculated in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board, this press release contains non-IFRS financial measures of EBITDA (EBITDA loss), Adjusted EBITDA (Adjusted EBITDA loss), non-IFRS net profit (loss), non-IFRS gross profit, non-IFRS gross margin and non-IFRS basic earnings (loss) per share or ADS for the periods presented. The Company defines EBITDA (EBITDA loss) as net profit (loss) before depreciation, amortization and impairment of intangible assets (if any), financial income (expense) and income tax; defines Adjusted EBITDA (Adjusted EBITDA loss) as EBITDA (EBITDA loss) as further adjusted to remove the impact of (i) impairment of goodwill (if any); and (ii) share-based compensation; defines non-IFRS net profit (loss) as net profit (loss) before depreciation, amortization and impairment of intangible assets (if any), impairment of goodwill (if any), financial income (expense) effects primarily related to derivative financial instruments as well as long-term loans, deferred tax effects and share-based compensation; defines non-IFRS gross profit as gross profit adjusted to remove the impact of depreciation, amortization and impairment of intangible assets and share-based compensation recorded under cost of revenues; defines non-IFRS gross margin as the percentage of the non-IFRS gross profit out of revenues; and defines non-IFRS basic earnings (loss) per share or ADS as non-IFRS net profit (loss) divided by the weighted average number of ordinary shares or ADSs. The Company’s management believes the non-IFRS financial information provided in this press release is useful to investors’ understanding and assessment of the Company’s ongoing operations. Management also uses both IFRS and non-IFRS information in evaluating and operating its business internally, and as such deemed it important to provide this information to investors. The non-IFRS financial measures disclosed by the Company should not be considered in isolation, or as a substitute for, or superior to, financial measures calculated in accordance with IFRS, and the financial results calculated in accordance with IFRS and reconciliations to those financial statements should be carefully evaluated. Investors are encouraged to review the reconciliations of these non-IFRS measures to their most directly comparable IFRS financial measures provided in the financial statement tables herein.

Other Metrics

NRR is a key indicator of customer base health and revenue expansion. It is based on NRR point in time, which measures the revenue growth of current customers over the past four quarters, compared to the revenue generated from these customers during the same period a year earlier.

NRR is calculated as an average of the NRR points in time for the end of the current period and the three preceding quarters.

NRR > 1 (or 100%): Indicates revenue growth driven by existing customers, where upsells and cross-sells outweigh churn.

NRR < 1 (or 100%): Shows revenue loss due to churn exceeding gains from upsells or cross-sells.

Non-IFRS Financial Measures


(in millions of U.S. dollars, rounded)

The following tables present the reconciled effect of the above on the Company’s Adjusted EBITDA; non-IFRS net profit; and non-IFRS gross profit for the six and three months ended June 30, 2025 and 2024, and the year ended December 31, 2024:

    For the

Six Months Ended

June 30,
    For the

Three Months Ended

June 30,
    For the

Year Ended

December 31,
 
    2025     2024     2025     2024     2024  
Net profit (loss) from continuing operations     0.7       1.1       0.3       (0.3 )     5.8  
Adjustments:                                        
Depreciation and amortization     0.3       0.3       0.2       0.1       0.6  
Financial expenses (income), net     (0.7 )     3.4       (0.5 )     2.5       (0.4 )
Tax expense     0.3       0.8       0.1       0.5       1.4  
EBITDA     0.6       5.6       0.1       2.8       7.4  
Adjustments:                                        
Share-based compensation     1.7       1.0       0.9       0.6       2.0  
Adjusted EBITDA for the period     2.3       6.6       1.0       3.4       9.4  

    For the

Six Months Ended

June 30,
    For the

Three Months Ended

June 30,
    For the

Year Ended

December 31,
 
    2025     2024     2025     2024     2024  
Net profit (loss) from continuing operations     0.7       1.1       0.3       (0.3 )     5.8  
Adjustments:                                        
Depreciation, amortization and impairment of intangible assets     0.3       0.3       0.2       *       0.6  
Financial expense (income), net effects     (0.1 )     3.3       *       2.5       0.1  
Deferred tax effects     (0.3 )     (0.1 )     (0.2 )     *       (0.1 )
Share-based compensation     1.7       1.0       0.9       0.6       2.0  
Non-IFRS net profit for the period     2.3       5.6       1.2       2.8       8.4  

*  Less than $0.1 million

    For the

Six Months Ended

June 30,
    For the

Three Months Ended

June 30,
    For the

Year Ended

December 31,
 
    2025     2024     2025     2024     2024  
Gross profit from continuing operations     10.2       13.4       5.4       6.8       23.9  
Adjustments:                                        
Depreciation, amortization and impairment of intangible assets     0.3       0.3       0.2       0.1       0.6  
Share-based compensation     *       *       *       *       *  
Non-IFRS gross profit for the period     10.5       13.7       5.6       6.9       24.5  

*  Less than $0.1 million

About Alarum Technologies Ltd.

Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) is a global provider of web data collection solutions, empowering organizations to gain a competitive edge by streamlining the collection, extraction, and analysis of large-scale structured data from public online sources. Our data collection solutions by NetNut, are based on our world’s fastest and most advanced and secured hybrid proxy network, which comprises both exit points based on our proprietary reflection technology and hundreds of servers located at our ISP partners around the world. Pushing the boundaries of innovation in data collection, we are building a robust platform, complemented by the Website Unblocker, Data Collector, Data Sets and AI data collector. As the impact of the AI revolution unfolds, Alarum, with its robust market-leading data collection offerings is preparing itself to play a meaningful role as the world reshapes in a new form.

For more information about Alarum and its web data collection solutions, please visit www.alarum.io.

Follow us on LinkedIn

Follow us on X

Subscribe to our YouTube channel

Investor Relations Contact:

[email protected]



GlobalFoundries Announces Production Release of 130CBIC SiGe Platform for High-Performance Smart Mobile, Communication and Industrial Applications

Industry’s first high-performance complementary BiCMOS technology delivers performance and power advantages for essential markets and applications

SANTA CLARA, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) — Today at its annual Technology Summit in California, GlobalFoundries (GF)(Nasdaq: GFS) announced the production release of its 130nm complementary Bi-CMOS (CBIC) platform, the company’s highest-performance silicon germanium (SiGe) technology to date.

Now available for design with a process design kit (PDK), 130CBIC delivers unmatched performance with NPN transistors exceeding 400 GHz ft/fmax and PNP transistors surpassing 200 GHz—making it the only high-performance SiGe platform capable of addressing multiple key markets including smartphones, wireless infrastructure, optical networking, satellite communications and industrial IoT.

Developed and manufactured at GF’s facility in Burlington, Vermont, 130CBIC is optimized to push the limits of RF performance in connected applications while reducing cost. For cellular smartphones, the platform enables low-noise amplifiers (LNAs) that reduce current consumption while maintaining ultra-low noise figure, helping to reduce battery drain. In the datacenter, the platform’s high-performance PNP transistors enable innovative amplifier topologies that deliver high gain-bandwidth at lower power for high-speed analog and optical networking. The platform also supports advanced mmWave industrial radar applications exceeding 100GHz, enabling high resolution sensing and distance ranging in a reduced form factor.

“130CBIC represents a major milestone in our SiGe roadmap, setting a new benchmark for performance for the broad spectrum of high-growth markets that rely on advanced RF technologies for high-speed, energy-efficient connectivity,” said Shankaran Janardhanan, senior vice president of GF’s RF product line. “By combining industry-leading transistor performance with a low-mask count process, we’re opening new avenues of RF innovation to our customers across the board and enabling them to ramp new technologies to market faster.”

130CBIC is available for prototyping through GF’s GlobalShuttle multi-project wafer program, with shuttles scheduled through 2025 and 2026. RF reference designs are available through GF’s self-service GF Connect portal to help jumpstart the design process.

About GF

GlobalFoundries (GF) is a leading manufacturer of essential semiconductors the world relies on to live, work and connect. We innovate and partner with customers to deliver more power-efficient, high-performance products for the automotive, smart mobile devices, internet of things, communications infrastructure and other high-growth markets. With our global manufacturing footprint spanning the U.S., Europe, and Asia, GF is a trusted and reliable source for customers around the world. Every day, our talented global team delivers results with an unyielding focus on security, longevity, and sustainability. For more information, visit www.gf.com.

Forward-looking information

This news release may contain forward-looking statements, which involve risks and uncertainties. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. GF undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Media Contact:

Stephanie Gonzalez
[email protected]